Zealand Pharma A/S (ZLDPF)
USD 75.15
(6.85%)
USD 75.15
(6.85%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 119.23 Million DKK | -73.11% |
| 2022 | 443.47 Million DKK | -43.68% |
| 2021 | 787.42 Million DKK | 557.02% |
| 2020 | 119.84 Million DKK | 39.75% |
| 2019 | 85.76 Million DKK | 0.0% |
| 2018 | - DKK | -100.0% |
| 2017 | 135.73 Million DKK | -59.15% |
| 2016 | 332.24 Million DKK | 6.16% |
| 2015 | 312.95 Million DKK | 14.98% |
| 2014 | 272.17 Million DKK | 0.0% |
| 2013 | - DKK | 0.0% |
| 2012 | - DKK | 0.0% |
| 2011 | - DKK | 0.0% |
| 2010 | - DKK | 0.0% |
| 2009 | - DKK | 0.0% |
| 2008 | - DKK | -100.0% |
| 2007 | 6.11 Million DKK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 389.99 Million DKK | 0.21% |
| 2024 Q1 | 389.18 Million DKK | 226.41% |
| 2023 FY | 119.23 Million DKK | -73.11% |
| 2023 Q3 | 116.05 Million DKK | -0.69% |
| 2023 Q2 | 116.86 Million DKK | -77.2% |
| 2023 Q1 | 512.55 Million DKK | 15.58% |
| 2023 Q4 | 119.23 Million DKK | 2.73% |
| 2022 Q1 | 790.19 Million DKK | 0.35% |
| 2022 FY | 443.47 Million DKK | -43.68% |
| 2022 Q4 | 443.47 Million DKK | -10.54% |
| 2022 Q3 | 495.72 Million DKK | 2.12% |
| 2022 Q2 | 485.42 Million DKK | -38.57% |
| 2021 Q2 | 143.77 Million DKK | 11.7% |
| 2021 FY | 787.42 Million DKK | 557.02% |
| 2021 Q4 | 787.42 Million DKK | 454.4% |
| 2021 Q3 | 142.03 Million DKK | -1.21% |
| 2021 Q1 | 128.71 Million DKK | 7.4% |
| 2020 Q1 | 101.2 Million DKK | 18.01% |
| 2020 Q3 | 133.5 Million DKK | -2.47% |
| 2020 Q4 | 119.84 Million DKK | -10.23% |
| 2020 FY | 119.84 Million DKK | 39.75% |
| 2020 Q2 | 136.88 Million DKK | 35.25% |
| 2019 Q3 | 68.49 Million DKK | 1953.06% |
| 2019 Q1 | 5.94 Million DKK | 0.0% |
| 2019 Q2 | 3.33 Million DKK | -43.91% |
| 2019 FY | 85.76 Million DKK | 0.0% |
| 2019 Q4 | 85.76 Million DKK | 25.22% |
| 2018 Q4 | - DKK | 0.0% |
| 2018 Q2 | 143.43 Million DKK | 6.92% |
| 2018 FY | - DKK | -100.0% |
| 2018 Q1 | 134.14 Million DKK | -1.17% |
| 2018 Q3 | - DKK | -100.0% |
| 2017 Q4 | 135.73 Million DKK | -4.34% |
| 2017 FY | 135.73 Million DKK | -59.15% |
| 2017 Q3 | 141.89 Million DKK | -2.84% |
| 2017 Q2 | 146.05 Million DKK | -9.56% |
| 2017 Q1 | 161.48 Million DKK | -51.39% |
| 2016 Q1 | 301.93 Million DKK | -3.52% |
| 2016 FY | 332.24 Million DKK | 6.16% |
| 2016 Q4 | 332.24 Million DKK | 6.44% |
| 2016 Q3 | 312.14 Million DKK | 0.3% |
| 2016 Q2 | 311.21 Million DKK | 3.08% |
| 2015 Q2 | 301.11 Million DKK | -2.45% |
| 2015 FY | 312.95 Million DKK | 14.98% |
| 2015 Q3 | 333.23 Million DKK | 10.67% |
| 2015 Q1 | 308.68 Million DKK | 13.42% |
| 2015 Q4 | 312.95 Million DKK | -6.09% |
| 2014 Q3 | - DKK | 0.0% |
| 2014 FY | 272.17 Million DKK | 0.0% |
| 2014 Q4 | 272.17 Million DKK | 0.0% |
| 2014 Q2 | - DKK | 0.0% |
| 2014 Q1 | - DKK | 0.0% |
| 2013 FY | - DKK | 0.0% |
| 2013 Q1 | - DKK | 0.0% |
| 2013 Q4 | - DKK | 0.0% |
| 2013 Q3 | - DKK | 0.0% |
| 2013 Q2 | - DKK | 0.0% |
| 2012 Q3 | - DKK | 0.0% |
| 2012 Q1 | - DKK | 0.0% |
| 2012 Q4 | - DKK | 0.0% |
| 2012 Q2 | - DKK | 0.0% |
| 2012 FY | - DKK | 0.0% |
| 2011 FY | - DKK | 0.0% |
| 2011 Q3 | - DKK | 0.0% |
| 2011 Q1 | - DKK | 0.0% |
| 2011 Q2 | - DKK | 0.0% |
| 2011 Q4 | - DKK | 0.0% |
| 2010 Q4 | - DKK | 0.0% |
| 2010 FY | - DKK | 0.0% |
| 2009 FY | - DKK | 0.0% |
| 2008 FY | - DKK | -100.0% |
| 2007 FY | 6.11 Million DKK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.92 Million USD | -6093.766% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -189.372% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -29570.349% |
| SQZ Biotechnologies Company | 27.47 Million USD | -334.021% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -5026.066% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -174.895% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -300.542% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -12473.41% |
| Marizyme, Inc. | 18.71 Million USD | -536.998% |
| Genus plc | 233.1 Million USD | 48.85% |
| Pharming Group N.V. | 171.54 Million USD | 30.496% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -13325.834% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -8774.026% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -15797.333% |
| ContraFect Corporation | 2.88 Million USD | -4038.494% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -8143.686% |
| IMV Inc. | 28.88 Million USD | -312.791% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -2007.15% |
| ONE Bio Corp. | 19.71 Million USD | -504.767% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -107.396% |
| Mesoblast Limited | 118.7 Million USD | -0.446% |
| MultiCell Technologies, Inc. | 202.58 USD | -58855660.687% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -260.201% |
| Genscript Biotech Corporation | 417.73 Million USD | 71.458% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -18823.084% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -9606.43% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -2792.558% |
| Biomind Labs Inc. | 735.54 Thousand USD | -16109.815% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -3839.936% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -817.366% |
| Skye Bioscience, Inc. | 4.61 Million USD | -2483.383% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -33046.146% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -3968.744% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -84150.767% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -87901.063% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -1930.798% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -463487.231% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -7876.579% |
| Q BioMed Inc. | 4.1 Million USD | -2800.987% |
| GB Sciences, Inc. | 1.75 Million USD | -6677.1% |
| Alpha Cognition Inc. | 1.22 Million USD | -9669.972% |
| CSL Limited | 12.18 Billion USD | 99.021% |
| Agentix Corp. | 50 Thousand USD | -238360.0% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | -76.264% |
| Enzolytics Inc. | 996.33 Thousand USD | -11866.823% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 6.49 Million USD | -1736.851% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -46548.565% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -5179.446% |
| argenx SE | 20 Million USD | -496.15% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -161.699% |
| HST Global, Inc. | 98.31 Thousand USD | -121168.524% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -47837.44% |
| Halberd Corporation | 150 Thousand USD | -79386.667% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -1585.751% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -1165963.57% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -4301.738% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -4872.632% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -51899.424% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -80106.385% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -59331.95% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | -5319.841% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -486.531% |
| Kadimastem Ltd | 891.22 Thousand USD | -13278.2% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | -2430.661% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -47557.305% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | 33.6 Thousand USD | -354687.836% |
| Cell Source, Inc. | 9.25 Million USD | -1188.392% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -15666.909% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -15666.909% |
| Affymax, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -24519.851% |
| Itoco Inc. | 228.37 Thousand USD | -52107.534% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -56413.805% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -2292.735% |
| International Stem Cell Corporation | 4.17 Million USD | -2753.758% |
| CytoDyn Inc. | 30.07 Million USD | -296.429% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -33786.888% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -1424.688% |
| SYBLEU INC | 477.5 Thousand USD | -24869.634% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -97230.612% |
| Rebus Holdings, Inc. | 310 Thousand USD | -38361.29% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -2417.907% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -190933.919% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -5367.009% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -1333.742% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -1288.818% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -7565.163% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -44388.806% |
| Neutra Corp. | 54.15 Thousand USD | -220060.278% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -6415.301% |
| PureTech Health plc | 25.51 Million USD | -367.349% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -9639.215% |
| IXICO plc | 472.02 Thousand USD | -25159.362% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -669.176% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -91.494% |
| CSL Limited | 12.18 Billion USD | 99.021% |
| Cellectis S.A. | 92.77 Million USD | -28.513% |